Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system

被引:16
|
作者
Zhu, Yanmin [1 ]
Coyle, D. Tyler [2 ]
Mohamoud, Mohamed [2 ]
Zhou, Esther [2 ]
Eworuke, Efe [2 ]
Dormitzer, Catherine [2 ]
Staffa, Judy [2 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, 1225 Ctr Dr,HPNP Bldg,Rm 3334,POB 100496, Gainesville, FL 32610 USA
[2] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
关键词
Benzodiazepines; Buprenorphine; Medication-Assisted treatment; Concomitant use; MONITORING PROGRAMS; UNITED-STATES; OVERDOSE DEATHS; DRUG; TRENDS; PAIN; DEPENDENCE; PHYSICIANS; GUIDELINE; ADDICTION;
D O I
10.1016/j.drugalcdep.2018.02.019
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Despite clinical guidelines discouraging the practice, it is well-documented that the concomitant use of benzodiazepines and opioid analgesics occurs regularly. Information on concomitant use of buprenorphine for medication-assisted treatment (MAT) of opioid use disorder (OUD) and benzodiazepines, however, is limited. Thus, we aimed to describe real-world drug dispensing patterns for the concomitant use of buprenorphine products approved for MAT and benzodiazepines. Methods: We examined concomitant use of buprenorphine for MAT and benzodiazepines using the 2013 Prescription Behavior Surveillance System data from eight states. For prescription-level analysis, we estimated the proportion of concomitant buprenorphine and benzodiazepine prescriptions and the proportions of concomitant prescriptions prescribed by the same provider (co-prescribing) and dispensed by the same pharmacy (co-dispensing) for each state. For patient-level analysis, we calculated the proportion of patients with >= 1 buprenorphine therapy episode overlapping with a benzodiazepine episode, i.e., concomitant users, and the proportion of concomitant users who experienced co-prescribing or co-dispensing. Results: In 2013, 1,925,072 prescriptions of buprenorphine products for MAT were dispensed to 190,907 patients in eight states. Approximately 1 in 8 buprenorphine prescriptions was used concomitantly with >= 1 benzodiazepine prescription(s). Co-prescribing proportions ranged from 22.2 to 64.6% across states, while co-dispensing proportions ranged from 54.7 to 91.0%. Approximately 17.7% of patients had > 1 buprenorphine episode overlapping a benzodiazepine episode for >= 7 cumulative days' supply. Among these patients, 33.1-65.2% experienced co-prescribing, and 65.1-93.3% experienced co-dispensing. Conclusions: The concomitant use of buprenorphine for MAT and benzodiazepines occurs frequently, with variations by state in co-prescribing and co-dispensing.
引用
收藏
页码:221 / 226
页数:6
相关论文
共 50 条
  • [1] Concomitant Use of Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder and Benzodiazepines: Using the Prescription Behavior Surveillance System
    Zhu, Yanmin
    Coyle, D. Tyler
    Mohamoud, Mohamed
    Zhou, Esther
    Eworuke, Efe
    Dormitzer, Catherine
    Staffa, Judy
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 16 - 17
  • [2] Medication-assisted treatment for opioid use disorder
    Kaplan, Louise
    [J]. NURSE PRACTITIONER, 2019, 44 (03): : 10 - 12
  • [3] Compliance with Buprenorphine Medication-Assisted Treatment and Relapse to Opioid Use
    Tkacz, Joseph
    Severt, Jamie
    Cacciola, John
    Ruetsch, Charles
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2012, 21 (01): : 55 - 62
  • [4] Review of medication-assisted treatment for opioid use disorder
    Ghanem, Nessreen
    Dromgoole, Devin
    Hussein, Ahmad
    Jermyn, Richard T.
    [J]. JOURNAL OF OSTEOPATHIC MEDICINE, 2022, 122 (07): : 367 - 374
  • [5] Medication-Assisted Treatment for Opioid-Use Disorder
    Oesterle, Tyler S.
    Thusius, Nuna J.
    Rummans, Teresa A.
    Gold, Mark S.
    [J]. MAYO CLINIC PROCEEDINGS, 2019, 94 (10) : 2072 - 2086
  • [6] The NP and medication-assisted treatment for opioid use disorder
    Warner, Shirley A.
    Strickland, Daniel M.
    [J]. NURSE PRACTITIONER, 2022, 47 (07): : 10 - 13
  • [7] The role of NPs in medication-assisted treatment for opioid use disorder
    Cotton, Brandi Parker
    Ferszt, Ginette G.
    [J]. NURSE PRACTITIONER, 2018, 43 (05): : 8 - 8
  • [8] Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder
    Feder, Kenneth A.
    Krawczyk, Noa
    Saloner, Brendan
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2017, 60 (06) : 747 - 750
  • [9] Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder
    Krans, Elizabeth E.
    Kim, Joo Yeon
    James, Alton Everette, III
    Kelley, David
    Jarlenski, Marian P.
    [J]. OBSTETRICS AND GYNECOLOGY, 2019, 133 (05): : 943 - 951
  • [10] Medication-assisted recovery for opioid use disorder: A guide
    Posen, Andrew
    Keller, Eden
    Elmes, Abigail T.
    Messmer, Sarah
    Gastala, Nicole
    Neeb, Christine
    Jarrett, Jennie B.
    [J]. JOURNAL OF FAMILY PRACTICE, 2023, 72 (04): : 164 - 171